Craig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Ligand Pharma (LGND) with a $370 price target. Hewitt, who covers the healthcare sector, has a 47.4% success rate. This contrasts with the broader market consensus, which suggests a Strong Buy rating for LGND with an average price target of $355.13.
In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Ligand Pharma, with a price target of $370.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Hewitt covers the Healthcare sector, focusing on stocks such as MaxCyte, Ligand Pharma, and Codexis. According to TipRanks, Hewitt has an average return of 3.4% and a 47.40% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $355.13 average price target.